Earlier this year, Pfizer Pharmaceuticals experienced a temporary interruption in the supply of the Genotropin 5 and 12mg cartridges, as well as all Mini Quick devices. According to the Commercial Brand Lead for the US, Michael Harris of Pfizer Pharmaceuticals, the interruption was due to a manufacturing issue in fall of 2019 at the Pfizer Puurs manufacturing facility in Belgium. The issue required an investigation which caused an interruption in the supply of Genotropin. The issue was quickly resolved and had no impact on the safety or efficacy of the medication and manufacturing of Genotropin was resumed.
According to Mr. Harris, the supply of the 5 and 12 mg cartridges has been fully restored and patients should be no difficulty obtaining them. The Mini Quick devices continue to be sporadically in short supply. Pfizer anticipates full resolution of the problem by September 2020 and will continue to do everything they can to maintain the supply of the Mini Quicks specifically in the smallest doses. These should continue to be available for pharmacy dispensing.
PWSA USA’s Medical and Research Coordinator, Mary Burr, has beein in direct communication with the Pfizer drug management team and received the following update on June 30th:
“There is absolutely no validity to the statement that the MiniQuicks will never be available for distribution. Pfizer is absolutely committed to restoring reliable supply of each of the 10 MiniQuick presentations, in the same way they were previously. Unfortunately, the supply situation with the MiniQuick presentations currently does remain in flux, but I want to emphasize our commitment to bringing these back for distribution in a continuous and reliable fashion. At this time, we are expecting the MiniQuick presentations to begin to consistently return to stock late this summer, and we are currently hoping for a complete return across all presentations by the September/October timeframe. Please let me know if you have concerns about specific presentations and I can try to keep you in the loop as to when those become more reliably in stock.” – Michael Harris, US Commercial Brand Lead Pfizer Pharmaceuticals.
If you are concerned your child might be impacted by the shortage, please consider the following options/steps: Call your pharmacy and ask if your prescription will be affected by the shortage. If so, reach out to your child’s endocrinologist to discuss potential options. A switch of products or administration device might be all that is needed. All growth hormone medications are basically the same and differ only in the devices used to administer the medication and in some cases the preservatives used to suspend the medication might also be different. If you have any questions, please call Mary Burr at (800) 926-4797). She is looking forward to helping your family navigate any potential shortages.